Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
62 hedge funds and large institutions have $7.97M invested in Zynerba Pharmaceuticals, Inc in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 6 closing their positions.
467% more call options, than puts
Call options by funds: $68K | Put options by funds: $12K
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
11% more funds holding
Funds holding: 56 → 62 (+6)
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
36% less capital invested
Capital invested by funds: $12.5M → $7.97M (-$4.57M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$424K |
| 2 |
Millennium Management
New York
|
+$334K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$263K |
| 4 |
Two Sigma Investments
New York
|
+$139K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$615K |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$375K |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$214K |
| 4 |
PCM
Penserra Capital Management
Orinda,
California
|
-$155K |
| 5 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
-$122K |
ZYNE Hedge Fund Activity: Q3 2022 in Review
62 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q3 2022, worth a combined $7.97M — down 36% from $12.5M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ZYNE positions and 6 closed out — a net gain of 6 holders — while 13 added to existing stakes and 16 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $424K. The largest seller was D.E. Shaw & Co, cutting an estimated $615K.
- 62 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q3 2022, up from 56 in Q2 2022.
- Funds reported $7.97M of Zynerba Pharmaceuticals, Inc stock for Q3 2022, down 36% quarter-over-quarter.
- 12 funds opened new Zynerba Pharmaceuticals, Inc positions in Q3 2022 and 6 closed out, a net change of +6 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q3 2022 was Renaissance Technologies, an estimated $424K added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q3 2022 was D.E. Shaw & Co, an estimated $615K sold.
Based on aggregated 13F filings for Q3 2022.